Featured Members

How did you become interested in the field? I was working in 1981 as an organic chemist at NIH in the former FDA Bureau of Biologics (now Center for Drug Evaluation & Research), and was asked to help clone the gene for human C-reactive protein by making the required hybridization probe—a mixed-sequence 11-mer oligodeoxynucleotide,

Takenori Shimo received both his B.S. and M.Sc. in Pharmaceutical Sciences from Osaka University, Japan. He is currently a doctoral candidate in the Graduate School of Pharmaceutical Sciences, Osaka University. His research interests include nucleic acid chemistry, especially modulating splicing by using antisense oligonucleotides.

Paloma H. Giangrande, PhD Associate Professor, Department of Internal Medicine, University of Iowa Scientific Advisory Council Member, Oligonucleotide Therapeutics Society Giangrande_Photo Dr. Paloma H. Giangrande Paloma H. Giangrande, PhD, is an Associate Professor in the Department of Internal Medicine at The University

Science: Q: Paul Zamecnik and Mary Stephenson in 1978 reported the very first studies on antisense mechanisms of gene silencing. Since the inception of this field – how far have we come – both in basic and therapeutic research & development? A: The original antisense mechanism has been joined